Product Description
Dapansutrile (OLT1177) acts as a NLRP3 inflammasome inhibitor. It is a clinical candidate that is being developed by Olatec Therapeutics. Inhibition of the NLRP3 inflammasome reduces maturation of the pro-inflammatory, disease-associated cytokines IL-1beta and IL-18 [1]. Immunoprecipitation and FRET analysis indicates that OLT1177 inhibits inflammasome oligomerization by blocking NLRP3-ASC, and NLRP3-caspase-1 interaction, but may also directly target NLRP3 (as assessed by inhibition of recombinant NLRP3 ATPase activity by dapansutrile). (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10056)
Mechanisms of Action: NLRP3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Olatec
Company Location: Eastern America
Company Founding Year: 2003
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Germany, Israel, Netherlands, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Olatec Therapeutics, Inc. presented P0 Parkinson's Disease results on 2026-01-20 for Dapansutrile
Highest Development Phases
Phase 3: Acute Pain|Arthralgia|Gout|Inflammation
Phase 2: Melanoma|Parkinson's Disease|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06047262 |
Dapan-Dia | P2 |
Recruiting |
Type 2 Diabetes |
2028-07-31 |
50% |
2026-02-26 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT07157735 |
DAPA-PD | P2 |
Recruiting |
Parkinson's Disease|Inflammation |
2027-05-01 |
12% |
2026-06-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04971499 |
Pro00108864 | P2 |
Active, not recruiting |
Melanoma |
2027-04-30 |
12% |
2026-02-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05658575 |
OLT1177-08 | P3 |
Recruiting |
Arthralgia|Inflammation|Acute Pain |
2026-12-31 |
13% |
2026-03-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
2024-518844-20-00 |
OLT1177-08 | P3 |
Recruiting |
Gout |
2025-09-30 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/24/2026 |
News Article |
First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases |
|
01/20/2026 |
News Article |
Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies |
|
10/02/2025 |
News Article |
Andy Cunningham Joins Olatec Therapeutics Board of Directors |
|
01/28/2025 |
News Article |
Marc Y. Donath MD, Renowned Immuno-Endocrinologist, Appointed to Olatec's Clinical Advisory Board |